23 results on '"Ranna, Vinisha"'
Search Results
2. Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines—part 1: vitamins, minerals, and nutritional supplements
- Author
-
Yarom, Noam, Hovan, Allan, Bossi, Paolo, Ariyawardana, Anura, Jensen, Siri Beier, Gobbo, Margherita, Saca-Hazboun, Hanan, kandwal, Abhishek, Majorana, Alessandra, Ottaviani, Giulia, Pentenero, Monica, Nasr, Narmin Mohammed, Rouleau, Tanya, Lucas, Anna Skripnik, Treister, Nathaniel Simon, Zur, Eyal, Ranna, Vinisha, Vaddi, Anusha, Cheng, Karis Kin Fong, Barasch, Andrei, Lalla, Rajesh V., and Elad, Sharon
- Published
- 2019
- Full Text
- View/download PDF
3. Is mechanical curettage with adjunct photodynamic therapy more effective in the treatment of peri-implantitis than mechanical curettage alone?
- Author
-
Ghanem, Alexis, Pasumarthy, Sandeep, Ranna, Vinisha, Kellesarian, Sergio Varela, Abduljabbar, Tariq, Vohra, Fahim, and Malmstrom, Hans
- Published
- 2016
- Full Text
- View/download PDF
4. A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions
- Author
-
Elad, Sharon, Ranna, Vinisha, Ariyawardana, Anura, Correa, Maria Elvira Pizzigatti, Tilly, Vanessa, Nair, Raj G, Rouleau, Tanya, Logan, Richard M, Pinto, Andres, Charette, Veronica, Saunders, Debbie P, Jensen, Siri Beier, and Viral Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO)
- Published
- 2017
- Full Text
- View/download PDF
5. Correction to:Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and Clinical Practice Guidelines – Part 1: vitamins, minerals and nutritional supplements (Supportive Care in Cancer, (2019), 27, 10, (3997-4010), 10.1007/s00520-019-04887-x)
- Author
-
Yarom, Noam, Hovan, Allan, Bossi, Paolo, Ariyawardana, Anura, Jensen, Siri Beier, Gobbo, Margherita, Saca-Hazboun, Hanan, Kandwal, Abhishek, Majorana, Alessandra, Ottaviani, Giulia, Pentenero, Monica, Nasr, Narmin Mohammed, Rouleau, Tanya, Lucas, Anna Skripnik, Treister, Nathaniel Simon, Zur, Eyal, Ranna, Vinisha, Vaddi, Anusha, Cheng, Karis Kin Fong, Barasch, Andrei, Lalla, Rajesh V., and Elad, Sharon
- Abstract
The original version of this paper contains a typographical error in the units: g/day was incorrectly written as mg/day. Specifically, on page 4005, paragraph 6: These studies demonstrated that glutamine at a dose range of 10–30 mg/day, delivered throughout the RT-CT, may be effective to prevent OM. it should read: These studies demonstrated that glutamine at a dose range of 10–30 g/day, delivered throughout the RT-CT, may be effective to prevent OM.
- Published
- 2021
6. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
- Author
-
Correa, M Elvira P, primary, Cheng, Karis Kin Fong, additional, Chiang, Karen, additional, Kandwal, Abhishek, additional, Loprinzi, Charles L, additional, Mori, Takehiko, additional, Potting, Carin, additional, Rouleau, Tanya, additional, Toro, Juan J, additional, Ranna, Vinisha, additional, Vaddi, Anusha, additional, Peterson, Douglas E, additional, Bossi, Paolo, additional, Lalla, Rajesh V, additional, and Elad, Sharon, additional
- Published
- 2019
- Full Text
- View/download PDF
7. Influence of the orthognathic surgical procedure Le Fort I osteotomy on the vascularity and neurosensory response of the dental pulp: A systematic review.
- Author
-
Ranna, Vinisha, Kellesarian, Sergio Varela, Feng, Changyong, Javed, Fawad, and Ghanem, Alexis
- Abstract
Objective: Abnormalities of the midface and maxilla are frequently corrected using Le Fort I surgery. This osteotomy passes near the apices of the maxillary teeth, severing the blood vessels and nerves supplying the teeth. The aim of this review was to determine the effect of Le Fort I osteotomy on pulpal vascularity and neurosensory response. Data Sources: A systematic search of the literature was performed in PubMed/Medline, Google Scholar, EMBASE, and ISI Web of Knowledge from 1969 up to and including December 2015 using the following key words: Le Fort 1, tooth vitality, maxillary osteotomy, pulp, orthognathic. Reference lists of relevant articles were hand-searched for additional articles. Results: Sixty-two studies were located by initial screening; 38 did not meet the eligibility criteria; three were excluded after full-text review, 13 were excluded after quality assessment, leaving nine studies eligible that met all inclusion criteria for this systematic review. The postoperative follow-up period of the included studies ranged from 3 months to 28 months. Five studies assessed pulpal blood flow using laser Doppler flowmetry and eight studies assessed the pulpal neurosensory response using electric pulp testing. Conclusion: There is a decrease in pulpal vascularity and neurosensory response following a Le Fort I osteotomy in the early postoperative period (1 to 10 days) that is likely temporary. Further controlled clinical studies with standardized parameters are required to determine the long-term effects of Le Fort I osteotomy on the vascular and neural healing of the dental pulp. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Effect of the video output of the dental operating microscope on anxiety levels in a pediatric population during restorative procedures
- Author
-
Sayed, Abrar, Ranna, Vinisha, Padawe, Dimple, and Takate, Vilas
- Subjects
Child health ,Health - Abstract
Byline: Abrar. Sayed, Vinisha. Ranna, Dimple. Padawe, Vilas. Takate Background: Adapting a child to the alien settings of a dental operatory is a major challenge to the dentist. Fear of [...]
- Published
- 2016
9. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
- Author
-
Elad, Sharon, Cheng, Karis Kin Fong, Lalla, Rajesh V., Yarom, Noam, Hong, Catherine, Logan, Richard M., Bowen, Joanne, Gibson, Rachel, Saunders, Deborah P., Zadik, Yehuda, Ariyawardana, Anura, Correa, Maria Elvira, Ranna, Vinisha, Bossi, Paolo, Arany, Praveen, Al‐Azri, Abdul Rahman, Blijlevens, Nicole, Hovan, Allan, Fregnani, Eduardo, and Fulton, Janet
- Subjects
MUCOSITIS ,MEDICAL personnel ,CANCER treatment ,ORAL cancer ,GUIDELINES ,META-analysis ,TUMOR treatment ,RESEARCH ,RESEARCH methodology ,SYSTEMATIC reviews ,MEDICAL cooperation ,EVALUATION research ,MEDICAL protocols ,COMPARATIVE studies ,TUMORS ,DISEASE complications - Abstract
Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis.Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions.Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents.
- Author
-
Yarom, Noam, Hovan, Allan, Bossi, Paolo, Ariyawardana, Anura, Jensen, Siri Beier, Gobbo, Margherita, Saca-Hazboun, Hanan, Kandwal, Abhishek, Majorana, Alessandra, Ottaviani, Giulia, Pentenero, Monica, Nasr, Narmin Mohammed, Rouleau, Tanya, Lucas, Anna Skripnik, Treister, Nathaniel Simon, Zur, Eyal, Ranna, Vinisha, Vaddi, Anusha, Barasch, Andrei, and Lalla, Rajesh V
- Subjects
META-analysis ,MUCOSITIS ,ORAL cancer ,HEAD & neck cancer ,HONEY ,CANCER patients ,PROBIOTICS ,CETUXIMAB ,THERAPEUTIC use of probiotics ,THERAPEUTIC use of antineoplastic agents ,HEAD tumors ,STOMATITIS ,MEDICINAL plants ,CENTRAL nervous system stimulants ,CHEWING gum ,SALIVA ,SYSTEMATIC reviews ,ANTINEOPLASTIC agents ,NECK tumors - Abstract
Objective: To update the clinical practice guidelines for the management of oral mucositis (OM) that were developed by the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). This part focuses on honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents.Methods: A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The body of evidence for each intervention, in each clinical setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, one of the following guidelines were determined: Recommendation, Suggestion, No Guideline Possible.Results: A total of 78 papers were identified within the scope of this section, of which 49 were included in this review and merged with nine publications that were reported in the previous guidelines update. A new Suggestion was made for honey (combined topical and systemic delivery) for the prevention of OM in head and neck cancer patients receiving radiotherapy with or without chemotherapy. A new Suggestion clarified that chewing gum is not effective for the prevention of OM in pediatric patients with hematological or solid cancer treated with chemotherapy. No guideline was possible for other interventions.Conclusions: Numerous natural products and herbal remedies were studied for the management of OM. Of the agents reviewed in this systematic review, a guideline in favor was made for honey (combined topical and systemic), while a guideline against was made for chewing gum. Additional research is warranted to clarify the potential of other interventions. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
11. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines.
- Author
-
Saunders, Deborah P., Rouleau, Tanya, Cheng, Karis, Yarom, Noam, Kandwal, Abhishek, Joy, Jamie, Bektas Kayhan, Kivanc, van de Wetering, Marianne, Brito-Dellan, Norman, Kataoka, Tomoko, Chiang, Karen, Ranna, Vinisha, Vaddi, Anusha, Epstein, Joel, Lalla, Rajesh V., Bossi, Paolo, Elad, Sharon, and Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
- Subjects
MUCOSITIS ,META-analysis ,ORAL cancer ,CANCER pain ,CANCER patients ,ANALGESICS ,THERAPEUTIC use of antineoplastic agents ,HEAD tumors ,STOMATITIS ,ANESTHETICS ,SYSTEMATIC reviews ,ANTI-infective agents ,ANTINEOPLASTIC agents ,MEDICAL protocols ,NECK tumors - Abstract
Purpose: To update the clinical practice guidelines for the use of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and/or treatment of oral mucositis (OM).Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: Recommendation, Suggestion, and No Guideline Possible.Results: A total of 9 new papers were identified within the scope of this section, adding to the 62 papers reviewed in this section previously. A new Suggestion was made for topical 0.2% morphine for the treatment of OM-associated pain in head and neck (H&N) cancer patients treated with RT-CT (modification of previous guideline). A previous Recommendation against the use of sucralfate-combined systemic and topical formulation in the prevention of OM in solid cancer treatment with CT was changed from Recommendation Against to No Guideline Possible. Suggestion for doxepin and fentanyl for the treatment of mucositis-associated pain in H&N cancer patients was changed to No Guideline Possible.Conclusions: Of the agents studied for the management of OM in this paper, the evidence supports a Suggestion in favor of topical morphine 0.2% in H&N cancer patients treated with RT-CT for the treatment of OM-associated pain. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.
- Author
-
Logan, Richard M., Al-Azri, Abdul Rahman, Bossi, Paolo, Stringer, Andrea M., Joy, Jamie K., Soga, Yoshihiko, Ranna, Vinisha, Vaddi, Anusha, Raber-Durlacher, Judith E., Lalla, Rajesh V., Cheng, Karis Kin Fong, Elad, Sharon, and Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
- Subjects
GROWTH factors ,MUCOSITIS ,HEMATOPOIETIC stem cell transplantation ,META-analysis ,ORAL cancer ,STEM cell transplantation ,THERAPEUTIC use of cytokines ,THERAPEUTIC use of antineoplastic agents ,GRANULOCYTE-macrophage colony-stimulating factor ,STOMATITIS ,SYSTEMATIC reviews ,ANTINEOPLASTIC agents ,MEDICAL protocols ,TUMORS ,RECOMBINANT proteins - Abstract
Purpose: To update the clinical practice guidelines for the use of growth factors and cytokines for the prevention and/or treatment of oral mucositis (OM).Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: recommendation, suggestion, and no guideline possible.Results: A total of 15 new papers were identified within the scope of this section and were merged with 51 papers that were reviewed in the previous guidelines update. Of these, 14, 5, 13, 2, and 1 were randomized controlled trials about KGF-1, G-CSF, GM-CSF, EGF, and erythropoietin, respectively. For the remaining agents there were no new RCTs. The previous recommendation for intravenous KGF-1 in patients undergoing autologous hematopoietic stem cell transplantation (HSCT) conditioned with high-dose chemotherapy and TBI-based regimens is confirmed. The previous suggestion against the use of topical GM-CSF for the prevention of OM in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation remains unchanged.Conclusions: Of the growth factors and cytokines studied for the management of OM, the evidence supports a recommendation in favor of KGF-1 and a suggestion against GM-CSF in certain clinical settings. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods.
- Author
-
Ranna, Vinisha, Cheng, Karis Kin Fong, Castillo, Daniel A., Porcello, Lorraine, Vaddi, Anusha, Lalla, Rajesh V., Bossi, Paolo, Elad, Sharon, and Mucositis Study group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO)
- Subjects
- *
ORAL cancer , *GUIDELINES , *MUCOSITIS , *CANCER treatment - Abstract
New studies and literature continue to emerge on the management of mucositis secondary to cancer therapy. The evidence-based clinical practice guidelines for mucositis were first published in 2004 and updated in 2007 and 2014 by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The existing 2014 guidelines for mucositis are being updated in line with new literature to inform clinical practice. This paper describes the materials and methods employed for the comprehensive updates to the guidelines for managing mucositis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.
- Author
-
Bowen, Joanne M., Gibson, Rachel J., Coller, Janet K., Blijlevens, Nicole, Bossi, Paolo, Al-Dasooqi, Noor, Bateman, Emma H., Chiang, Karen, de Mooij, Charlotte, Mayo, Bronwen, Stringer, Andrea M., Tissing, Wim, Wardill, Hannah R., van Sebille, Ysabella Z. A., Ranna, Vinisha, Vaddi, Anusha, Keefe, Dorothy MK., Lalla, Rajesh V., Cheng, Karis Kin Fong, and Elad, Sharon
- Subjects
MUCOSITIS ,META-analysis ,GASTROINTESTINAL cancer ,HYPERBARIC oxygenation ,SODIUM butyrate ,ORAL cancer - Abstract
Purpose: The aim of this study was to update the clinical practice guidelines for the use of agents for the prevention and/or treatment of gastrointestinal mucositis (GIM).Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, and No Guideline Possible.Results: A total of 78 papers across 13 interventions were examined of which 25 were included in the final review. No new guidelines were possible for any agent due to inadequate and/or conflicting evidence. Existing guidelines for probiotics and hyperbaric oxygen were unchanged.Conclusions: Of the agents studied for the prevention and treatment of GIM, the evidence continues to support use of probiotics containing Lactobacillus spp. for prevention of chemoradiotherapy and radiotherapy-induced diarrhea in patients with pelvic malignancy, and hyperbaric oxygen therapy to treat radiation-induced proctitis. Additional well-designed research is encouraged to enable a decision regarding palifermin, glutamine, sodium butyrate, and dietary interventions, for the prevention or treatment of GIM. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines.
- Author
-
Zadik, Yehuda, Arany, Praveen R., Fregnani, Eduardo Rodrigues, Bossi, Paolo, Antunes, Héliton Spindola, Bensadoun, René-Jean, Gueiros, Luiz Alcino, Majorana, Alessandra, Nair, Raj G., Ranna, Vinisha, Tissing, Wim J. E., Vaddi, Anusha, Lubart, Rachel, Migliorati, Cesar Augusto, Lalla, Rajesh V., Cheng, Karis Kin Fong, Elad, Sharon, and Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
- Subjects
MUCOSITIS ,META-analysis ,HEMATOPOIETIC stem cell transplantation ,ORAL cancer ,CANCER patients ,PHOTOTHERAPY - Abstract
Purpose: To systematically review the literature and update the evidence-based clinical practice guidelines for the use of photobiomodulation (PBM), such as laser and other light therapies, for the prevention and/or treatment of oral mucositis (OM).Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using PubMed and Web of Science. We followed the MASCC methods for systematic review and guidelines development. The rigorously evaluated evidence for each intervention, in each cancer treatment setting, was assigned a level-of-evidence (LoE). Based on the LoE, one of the following guidelines was determined: Recommendation, Suggestion, or No Guideline Possible.Results: Recommendations are made for the prevention of OM and related pain with PBM therapy in cancer patients treated with one of the following modalities: hematopoietic stem cell transplantation, head and neck (H&N) radiotherapy (without chemotherapy), and H&N radiotherapy with chemotherapy. For each of these modalities, we recommend 1-2 clinically effective protocols; the clinician should adhere to all parameters of the protocol selected. Due to inadequate evidence, currently, No Guideline Possible for treatment of established OM or for management of chemotherapy-related OM. The reported clinical settings were extremely variable, limiting data integration.Conclusions: The evidence supports the use of specific settings of PBM therapy for the prevention of OM in specific patient populations. Under these circumstances, PBM is recommended for the prevention of OM. The guidelines are subject to continuous update based on new published data. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
16. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines.
- Author
-
Ariyawardana, Anura, Cheng, Karis Kin Fong, Kandwal, Abhishek, Tilly, Vanessa, Al-Azri, Abdul Rahman, Galiti, Dimitra, Chiang, Karen, Vaddi, Anusha, Ranna, Vinisha, Nicolatou-Galitis, Ourania, Lalla, Rajesh V., Bossi, Paolo, Elad, Sharon, and Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO)
- Subjects
MUCOSITIS ,ANTI-inflammatory agents ,META-analysis ,ORAL cancer ,CANCER patients ,GUIDELINES - Abstract
Purpose: The aim of this systematic review was to update the clinical practice guidelines for the use of anti-inflammatory agents in the prevention and/or treatment of oral mucositis.Methods: A systematic review was conducted by the Multinational Association of Supportive Care in Cancer/ International Society of Oral Oncology (MASCC/ISOO) subcommittee on mucositis guideline update. The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the clinical practice guidelines published in 2014. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, and no guidelines.Results: A total of 11 new papers across five interventions were examined. The recommendation for the use of benzydamine mouthwash for the prevention of radiotherapy-induced mucositis remained unchanged. New suggestion for the use of the same for prevention of mucositis associated with chemoradiotherapy was made. No guideline was possible for any other anti-inflammatory agents due to inadequate and/or conflicting evidence.Conclusions: Of the anti-inflammatory agents studied for oral mucositis, the evidence supports the use of benzydamine mouthwash in the specific populations listed above. Additional well-designed research is needed on other (class of agents) interventions and in other cancer treatment settings. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
17. Effect of Nd:YAG laser‐assisted non‐surgical periodontal therapy on clinical periodontal and serum biomarkers in patients with and without coronary artery disease: A short‐term pilot study
- Author
-
Javed, Fawad, primary, Kellesarian, Sergio V., additional, Al‐Kheraif, Abdulaziz A., additional, Ranna, Vinisha, additional, Qadri, Talat, additional, Yunker, Michael, additional, Malmstrom, Hans, additional, and Romanos, Georgios E., additional
- Published
- 2016
- Full Text
- View/download PDF
18. Management of Invasive Cervical Resorption Involving the Pulp by Surgical and Restorative Therapy
- Author
-
Ranna, Vinisha, primary and Sayed, Abrar, additional
- Published
- 2015
- Full Text
- View/download PDF
19. Acute monoblastic leukemia (aleukemic leukemia) presenting as gingival enlargement
- Author
-
Kajale, ManasiM, primary, Umarji, HemantR, additional, Kadam, Sonali, additional, and Ranna, Vinisha, additional
- Published
- 2014
- Full Text
- View/download PDF
20. Correction to: Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and Clinical Practice Guidelines - Part 1: vitamins, minerals and nutritional supplements.
- Author
-
Yarom, Noam, Hovan, Allan, Bossi, Paolo, Ariyawardana, Anura, Jensen, Siri Beier, Gobbo, Margherita, Saca-Hazboun, Hanan, Kandwal, Abhishek, Majorana, Alessandra, Ottaviani, Giulia, Pentenero, Monica, Nasr, Narmin Mohammed, Rouleau, Tanya, Lucas, Anna Skripnik, Treister, Nathaniel Simon, Zur, Eyal, Ranna, Vinisha, Vaddi, Anusha, Cheng, Karis Kin Fong, and Barasch, Andrei
- Subjects
DIETARY supplements ,MINERAL supplements ,ORAL cancer ,VITAMINS ,CANCER patients - Abstract
A Correction to this paper has been published: https://doi.org/10.1007/s00520-021-06141-9 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines
- Author
-
Karis Kin Fong Cheng, Yoshihiko Soga, Vinisha Ranna, Rajesh V. Lalla, Abdul Rahman Al-Azri, Anusha Vaddi, Sharon Elad, Jamie K. Joy, Richard M. Logan, Andrea M. Stringer, Judith E. Raber-Durlacher, Paolo Bossi, Oral Medicine, Oral and Maxillofacial Surgery, Logan, Richard M, Al-Azri, Abdul Rahman, Bossi, Paolo, Stringer, Andrea M, Joy, Jamie K, Soga, Yoshihiko, Ranna, Vinisha, Vaddi, Anusha, Raber-Durlacher, Judith E, Lalla, Rajesh V, Cheng, Karis Kin Fong, and Elad, Sharon
- Subjects
Male ,Mucositis ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Antineoplastic Agents ,Hematopoietic stem cell transplantation ,Guidelines ,law.invention ,Oral mucositis ,03 medical and health sciences ,0302 clinical medicine ,SDG 17 - Partnerships for the Goals ,Randomized controlled trial ,law ,Neoplasms ,Medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Chemotherapy ,Stomatitis ,Cytokines ,Growth factors ,Systematic review ,Granulocyte-Macrophage Colony-Stimulating Factor ,Intercellular Signaling Peptides and Proteins ,Practice Guidelines as Topic ,Recombinant Proteins ,business.industry ,Cancer ,Guideline ,medicine.disease ,Transplantation ,Oncology ,030220 oncology & carcinogenesis ,business - Abstract
Purpose: To update the clinical practice guidelines for the use of growth factors and cytokines for the prevention and/or treatment of oral mucositis (OM).Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: recommendation,suggestion, and no guideline possible.Results: A total of 15 new papers were identified within the scope of this section and were merged with 51 papers that were reviewed inthe previous guidelines update. Of these, 14, 5, 13, 2, and 1 were randomized controlled trials about KGF-1, G-CSF, GM-CSF, EGF,and erythropoietin, respectively. For the remaining agents there were no new RCTs. The previous recommendation for intravenous KGF-1 in patients undergoing autologous hematopoietic stem cell transplantation (HSCT) conditioned with high-dose chemotherapy and TBI-based regimens is confirmed. The previous suggestion against the use of topical GM-CSF for the prevention of OM in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation remains unchanged.Conclusions: Of the growth factors and cytokines studied for the management of OM, the evidence supports a recommendation infavor of KGF-1 and a suggestion against GM-CSF in certain clinical settings. Refereed/Peer-reviewed
- Published
- 2020
22. Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents
- Author
-
Abhishek Kandwal, Allan Hovan, Paolo Bossi, Alessandra Majorana, Eyal Zur, Siri Beier Jensen, Tanya Rouleau, Margherita Gobbo, Vinisha Ranna, Karis Kin Fong Cheng, Rajesh V. Lalla, Noam Yarom, Nathaniel S. Treister, Hanan Saca-Hazboun, Narmin Mohammed Nasr, Anna Skripnik Lucas, Anusha Vaddi, Sharon Elad, Monica Pentenero, Giulia Ottaviani, Anura Ariyawardana, Andrei Barasch, Yarom, Noam, Hovan, Allan, Bossi, Paolo, Ariyawardana, Anura, Jensen, Siri Beier, Gobbo, Margherita, Saca-Hazboun, Hanan, Kandwal, Abhishek, Majorana, Alessandra, Ottaviani, Giulia, Pentenero, Monica, Nasr, Narmin Mohammed, Rouleau, Tanya, Lucas, Anna Skripnik, Treister, Nathaniel Simon, Zur, Eyal, Ranna, Vinisha, Vaddi, Anusha, Barasch, Andrei, Lalla, Rajesh V, Cheng, Karis Kin Fong, and Elad, Sharon
- Subjects
Mucositis ,medicine.medical_specialty ,Saliva ,Psychological intervention ,Antineoplastic Agents ,Chewing Gum ,Oral mucositis ,03 medical and health sciences ,0302 clinical medicine ,Complementary ,MISCELLANEOUS AGENTS ,medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Cancer ,Stomatitis ,Herbal ,Management ,Natural ,Traditional ,Plants, Medicinal ,business.industry ,Probiotics ,Nursing research ,Head and neck cancer ,Honey ,Guideline ,medicine.disease ,Oncology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Central Nervous System Stimulants ,business ,Oral mucositi - Abstract
Objective: To update the clinical practice guidelines for the management of oral mucositis (OM) that were developed by the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). This part focuses on honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. Methods: A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The body of evidence for each intervention, in each clinical setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, one of the following guidelines were determined: Recommendation, Suggestion, No Guideline Possible. Results: A total of 78 papers were identified within the scope of this section, of which 49 were included in this review and merged with nine publications that were reported in the previous guidelines update. A new Suggestion was made for honey (combined topical and systemic delivery) for the prevention of OM in head and neck cancer patients receiving radiotherapy with or without chemotherapy. A new Suggestion clarified that chewing gum is not effective for the prevention of OM in pediatric patients with hematological or solid cancer treated with chemotherapy. No guideline was possible for other interventions. Conclusions: Numerous natural products and herbal remedies were studied for the management of OM. Of the agents reviewed in this systematic review, a guideline in favor was made for honey (combined topical and systemic), while a guideline against was made for chewing gum. Additional research is warranted to clarify the potential of other interventions.
- Published
- 2020
23. Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines
- Author
-
Rajesh V. Lalla, Bronwen J. Mayo, Vinisha Ranna, Rachel J. Gibson, Emma Bateman, Paolo Bossi, Nicole M. A. Blijlevens, Wim J. E. Tissing, Noor Al-Dasooqi, Sharon Elad, Dorothy M. K. Keefe, Karen Chiang, Anusha Vaddi, Janet K. Coller, Hannah R. Wardill, Joanne M. Bowen, Ysabella Z.A. Van Sebille, Andrea M. Stringer, Charlotte E. M. de Mooij, Karis Kin Fong Cheng, Bowen, Joanne M, Gibson, Rachel J., Coller, Janet K., Blijlevens, Nicole, Bossi, Paolo, Al-Dasooqi, Noor, Bateman, Emma H, Chiang, Karen, de Mooij, Charlotte, Mayo, Bronwen, Stringer, Andrea M, Tissing, Wim, Wardill, Hannah R, van Sebille, Ysabella ZA, Ranna, Vinisha, Vaddi, Anusha, Keefe, Dorothy MK, Lalla, Rajesh V, Cheng, Karis Kin Fong, and Elad, Sharon
- Subjects
Mucositis ,medicine.medical_specialty ,Gastrointestinal ,CHEMOTHERAPY-INDUCED DIARRHEA ,Fibroblast Growth Factor 7 ,FRUCTO-OLIGOSACCHARIDE ,Glutamine ,Psychological intervention ,Guidelines ,COLORECTAL-CANCER ,03 medical and health sciences ,DOUBLE-BLIND ,0302 clinical medicine ,Quality of life ,QUALITY-OF-LIFE ,Neoplasms ,medicine ,clinical management ,Humans ,Proctitis ,030212 general & internal medicine ,COLONIC IRRIGATION ,guidelines ,Intensive care medicine ,MUCOSAL INJURY ,HYPERBARIC-OXYGEN ,Hyperbaric Oxygenation ,Stomatitis ,Clinical management ,Butyric Acid ,Chemoradiotherapy ,Practice Guidelines as Topic ,business.industry ,Nursing research ,Guideline ,medicine.disease ,gastrointestinal ,PATIENTS RECEIVING RADIOTHERAPY ,Oncology ,Palifermin ,030220 oncology & carcinogenesis ,business ,medicine.drug ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,ACUTE RADIATION ENTERITIS - Abstract
Contains fulltext : 208383.pdf (Publisher’s version ) (Closed access) PURPOSE: The aim of this study was to update the clinical practice guidelines for the use of agents for the prevention and/or treatment of gastrointestinal mucositis (GIM). METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, and No Guideline Possible. RESULTS: A total of 78 papers across 13 interventions were examined of which 25 were included in the final review. No new guidelines were possible for any agent due to inadequate and/or conflicting evidence. Existing guidelines for probiotics and hyperbaric oxygen were unchanged. CONCLUSIONS: Of the agents studied for the prevention and treatment of GIM, the evidence continues to support use of probiotics containing Lactobacillus spp. for prevention of chemoradiotherapy and radiotherapy-induced diarrhea in patients with pelvic malignancy, and hyperbaric oxygen therapy to treat radiation-induced proctitis. Additional well-designed research is encouraged to enable a decision regarding palifermin, glutamine, sodium butyrate, and dietary interventions, for the prevention or treatment of GIM.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.